CRMD - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to your CorMedix Second Quarter 2019 Earnings Conference Call. All lines have been place on a listen-only mode, and the floor will be open for your questions and comments following the presentation. [Operator Instructions]

At this time, it is my pleasure to turn the floor over to Mr. Dan Ferry. yours. is floor the Sir,

Dan Ferry

Good afternoon. investor second XXXX the welcome call. to conference CorMedix quarter And

Leading is, Cook, call President Vice He of the President, today Phoebe and is of Executive CorMedix; Jack joined CorMedix. General Officer Technical Counsel; by Armstrong, Executive Operations. Bob Mounts, Chief and Officer Khoso Financial Vice Baluch, Executive Chief

plans the in are everyone than not of call of management including the management’s of statements prospects, Private revenues fact we Neutrolin I and future known forward-looking for Any its Reform potential XXXX. clinical Before as other product following. costs, during development future Act position, acceptance the begin, forth but risks candidates, any would subject in These and that like other statements uncertainties meaning product statements the Litigation projected Securities and statements are about within make and candidates. and the program to, financial include, U.S. the to Company’s to what set goals historical and remind and of Neutrolin limited may regarding certain expectations, are other beliefs, market

and forward-looking to the about plans statements More timing, include projections the thereof, our development costs, clinical statements specifically, any results, interpretations as and

raising, product for market timing to component as other spending business expectations, transactions, candidates, Company's and future development and actions, and capital expectations product product the position, projections or licensing costs. and commercial and nature and manufacturing regulatory as to cash possible of anticipated our any expectations plans

regulatory and with available in CorMedix. greater not free are to of or described the are these at a limited SEC's commercialization. at important www.sec.gov, but charge which copies These projections request including, the detail Actual website or approvals, results risks upon development, of estimates variety from related filings from may to, clinical of uncertainties CorMedix SEC, to differ factors, materially in due

investors and forward-looking to these by undue on plans update goals that should these described forward-looking reliance in note as not statements. intend statements, actually or except the achieve not may Please required not statements, CorMedix these place does law. CorMedix

At please the call this Khoso, Baluch, to time, over go CorMedix. Chief pleasure to Khoso Officer ahead. my Executive of now it Mr. turn is

Khoso Baluch

Dan. everyone, us lock joining you, on you patients, Good continued call. that to will market solution. our thank we've for earnings as and hemodialysis to call a solution on Thank lock afternoon, bring focus for catheter the the and Today's this efforts U.S. catheter for commercial the analyzed opportunity Neutrolin

first Jack call, Paul For busy this the time, Phoebe, me. joining call, Armstrong, this and for Liz joining are at I and not are have Bob, work. but

cover We this during call. will four topics

First, on made significant an on pathway at for we've marketing a the Neutrolin application the progress or directed drug NDA. update for regulatory new a filling

or of control manufacturing the chain is component major NDA talk information CMC, currently a for will and and market. about U.S. the We chemistry, to that supply the establish we're then which underway

provide you position. We for then on talk will Company's lock additional use. the an as about only catheter Neutrolin’s update also solution not indications U.S. And we financial for for opportunity in hemodialysis, commercial a but then will the

hand With over to that, Mounts. me let Phoebe

Phoebe Mounts

regulatory in Thank the with Neutrolin Khoso. you our an provide update to is able be bring be on to progress the market you, here to and a to It the on required pleasure U.S. activities to

clinical clinical prevent and trial significant progresses trials most bloodstream Neutrolin provide who our substantial and new successful clinical and evidence farther to in the drug emphasis reliable patients emphasized discussions data the drug will on evidence place the clinical ongoing information data FDA on data prescribing our Without LOCK-IT-XXX physicians patients. the robust ensuring to last sponsors new is investigational that to of investigation, the accurate warrants During earnings drug the the trial to of no effectiveness and catheter-related adequate the medicine. protect provide an commercial for its process and efficiency towards milestone generated in and doubt, with hemodialysis Without infections safety be in and of FDA call, using a I distribution. from

We means to development in X saved means millions of of clinical study. than will trial two Phase July in based pleased more Company Neutrolin be years very by on that hemodialysis this conducted. is second the of dollars CorMedix’s Xth not press a have a were second release the patients This to that has able completed be on the Phase with What not hemodialysis and communications we needing patients. in X announce FDA, clinical

that is earlier revenue save to will generating lives and we catheter-related approved, able than begin to prevent Assuming Neutrolin anticipated. infections

As call, product Khoso a any believes potential the Neutrolin has be on discuss later to without CorMedix that insight. the competition will serious best-in-class

Adjudication with generated As were data we last requested FDA the the the efficacy information evaluating endpoints. it covered by on providing focused confirmation additional analyses. in the we assessments primary LOCK-IT-XXX. and the compiled And call, endpoint our the to and from data for conducted of information discussions Committee Clinical and study bloodstream catheter-related considerable subjects We earnings procedures on continue secondary our primary XXX with infections in for almost

the questions did the the for to is and FDA pleased further to questions to FDA any were addressed on full have the it. provided information NDA. analyses and report And not Additional endpoint. will information LOCK-IT-XXX are remaining prepared be FDA. on also Any submitted the the that when to These in secondary submitted were we was that report requested analyses

master in report the the the clinical NDA. We trial study continuing required the completing addressing all are for to work on of trial file and on documentation

secure if that from hemodialysis great believe on them news an to infection from Phase preventing not approval another be the can trial and both may also before for to timing NDA standpoint that X tremendous does it who news the catheter-related of need we are Neutrolin indication is bloodstream dialysis in available is individuals of expense use It submission patients. We conducted for FDA. for that be sooner

Just LOCK-IT-XXX will and to oncology prepared. that clear, included not indications of for additional be TPN use part described trial being and in not by clinical will were the Khoso NDA be be for the

We of solution with have uses lock in trial clinical working and the NDA TPN filed. finalizing protocols goal after are FDA for the on with the regulatory develop oncology and patient designs for had for hemodialysis the of discussions is to groups catheter pathway these

NDA important is the with drug were to manufacturing from information, in CMC used the maintain It new filing reviewed purity. Neutrolin application initiate investigation and extensive to and strength and on quality, discussions the in the FDA the ensure manufacturing FDA the for methods to to the FDA controls evidence, drug’s on that to in obtain identity, drug’s The by keep to drug addition the of mind began clinical including requires information before LOCK-IT-XXX. used approval

safety products. The drug the to of study investigational demands subjects controls before quality exposure

regulations proceed of detail chemistry manufacturer on a must a in the drug. product, obviously it drug be specific FDA's not prescribe and and dependent how designs However, as manufactures formulation the do which will

CMC Just in and FDA FDA we data discussions on been engaged with as engaged safety we have on with clinical effectiveness been Neutrolin, to information. have of support

expectations product with manufacturing the extensive be may in distribution detail. in must the FDA's the to to quality Armstrong to the variations be subjected Stability of that clinical be these Jack During drug and more process ensure is activities drug and are process be and and during to the encountered and will be review. product substance the throughout conditions, ensure guidance through from product. development, likely problems product commercial development drug of are needs demonstrated minimized FDA scaled data to NDA describe of validation in reproducible shown to But critical the reliable be up, introduced. Manufacturing studies. must addressed

the information, for pre-NDA the step of with quarter pre-NDA of FDA a towards the filing which is to The meet finalize submission on the the CMC NDA details is FDA. actual clinical discuss meeting, to administrative purpose data. planning the successful meeting CMC important NDA. for the the just in the are next meeting We the the with with After as fourth NDA agreements FDA to the is as

required will the is to the the taken submission. preparing its MDA, not the may FDA in that complete, period review refuse FDA If NDA care file XX-day in determine information is not and initial in

of topics be Limited the We discussion Drugs pathway, LPAD were by told Antibacterial will that pre-NDA at and Population to for for is the availability meeting or Pathway Antifungal of the FDA the meeting. pursuant the LPAD for One approval for NDA. the approval pre-NDA topic a of

of provided the You the whom was may safety and additional in recall drug the prevalence limited intended severity account takes for the intended the treatment the infection lack for determination and of its and the and is effectiveness treat alternative to drug into pathway the is use. of flexibility in population at FDA

FDA. with meeting pre-NDA the at LPAD on discussion our continue will We

July I on we to are on how to strengthened the comments would serve public program in present FDA's like we us to on note the allowing XXth. And industry. opportunity had be health to better the public think grateful that meeting our we and participate to can FDA for LPAD

emphasize determination product guidance, an comments we affirmative filed LPAD, to have need revising and development. FDA currently docket the FDA's in also LPAD the is with for to earlier for make eligibility

the to at security be join NDA. the will meeting discussion programs pre-NDA expedite review for of topic important to Another the

the of then the be For for in review the the FDA review the Neutrolin, received is that of for priority for received must in submitting eligible months. If XX designation for agrees makes have Requesting example, review FDA goal by period approval we to of NDA review. priority months FDA review, six NDA. Fast advance Track and the priority standard instead period from

for Just to are not goals absolute review the and be the agency clear, periods timelines.

in anticipating second have XXXX. current Based the with completed estimate, during our if on required. FDA Once approved may the the meeting fourth refine the estimates, our pre-NDA that our quarter, of we be we NDA will half we are

during marketing capabilities internally, for the needed U.S. I’m in call, the information last and that to the confident about have progress the to secure and in I be team As Neutrolin developing we stated our excited earnings successful. authorization

With the to supply provide Jack that, the like CMC I will an U.S. for Jack? and on to the work over call update turn you who would chain

Jack Armstrong

you, Thank Phoebe.

last Armstrong, a employee My been Technical and EVP for name CorMedix XXXX as the since and an for X.X years, have Operations. first I advisor as associated is with time as Jack full

I college know I to industry, bit in big my like years companies. the in U.S. you been a would of in the fortunate I of my Army, do have who those very Merck. for not In both me, began pharmaceutical career small After have the serving share For and to my working in industry pharma XX-plus-year background. worked and pharma little pharma

my companies. including drug as For development CEO have roles as been CMC, executive several related as senior well serving past to XX-plus-years, in manufacturing the positions and of

Neutrolin has last Neutrolin. five focused and CorMedix for U.S. manufacturing let’s been the on get Now, selling years. outside the

manufacturing and the well different give of have technical the carried validation technical, analytical We manufacturing which This Neutrolin’s the sites. successfully out has we of product understand the as enabled that quality as production controls comfort processes three that process, at with systems go it. and transfer successful manufacturing, should you

needed a of my that for requirements have the and foreign I including staff, for me me, And and submitted have with necessary sourcing, manufacturing, in experience, that the quality that very markets. competent past importantly, our breadth approved. control NDAs multiple working the U.S. is and depth team both ultimately and and were members has experienced successfully the distribution key

and with the FDA has have manufacturing concerning been As interactions proactive our Phoebe product said, positive.

to have outlined. we that that reason has cannot the fulfil FDA We the requirements no believe

for CMC have the required Many that. CorMedix, overlook of particularly importance inexperienced companies, section that done NDA. we is small, companies, not the the At

diligently with FDA product the have development during the on this We the topic working continually U.S. interacting and been in

quality develop the As by but the the for with sponsor Phoebe regulations the must and provide into quality pharmaceutical specific that framework designed demonstration be the created built of product, and manufacturing be must process the explained, from FDA working from the approval FDA CorMedix and based for required distribution, on based use. guidance drug for been to its the FDA. CMC has on commercial intended review information and guidance particular diligently

in be Our intended to to we our all on required update the and science for signal ensure It CMC NDA to discussions investors with importance of on ongoing that FDA CorMedix that it. July the understand from release an top are of X place. the was clear was be that of manufacturing a we life press will information data

manufactured for network and in In the initial are finished for product of finalizing in be supply process initial the addition, used the chain be U.S. will that distribution now we in The product launch the Europe. will

of in Further, manufacturing site we for sites at term, to a North qualify the second in our market. preliminary forecast, to needed forecast contract more on America. based Longer supply expect third-party two or volume order product to we our be manufacturing meet expect manufacturing to U.S.

built supply We suppliers, our chain have API, be manufacturing known robust and both as and efficient. selected to drug and infrastructure also substance our active

Neutrolin’s we with I'm our made. margins call, Further, sales. we worked while have able that last cost years pharma-like the provide will the U.S. of goods. say over several on have progress this I'm address I details hard to on to costs also And generate production not pleased gross very further can

I'm very and believe our we summary, our are track on filing. in So, progress pleased CMC with for

turn now to I'll call the Khoso. back over

Khoso Baluch

phase Thanks, Phoebe clearly continue Neutrolin. move forward we and for the as for for Jack work next important describing CorMedix to in

let insights. exciting me some cover Now,

in nephrologists, and CorMedix reimbursement. nurses reimbursement different TPN, for covering the all market last undertook of the During CorMedix in interviews segments, with almost payers providers, studies updated extensive XXX quarters, healthcare the evolving opportunity several including each and its plus several understanding U.S. the involved the the sectors of oncologists, environment Neutrolin with

The work years was solutions. wanted current of therapies market to done includes the is impact for of in the on and catheter that several lock previously care standard various of current we indications the and need understanding our old that the ensure the

in believe we we and patients prepared Neutrolin the better the to meet the result, a the FDA caregivers, the be of need should U.S. As would approves

catheter-related central Our Nurses substantial. that reinforced line associated clinically our and is the medical with use. that the infection physicians work a agree has need is concerning most belief complication

a Neutrolin’s is potential we best-in-class know, on that profile, based be our has as study product. convinced a Phase the game-changer. we And X to it clearly are now

are the significant reconfirmed need current unmet a Healthcare have solution. and practitioners providers considered solutions that medical seeking inadequate. better We

Neutrolin solution many healthcare very-high for a dread. all the bloodstream so segments Based acceptance and the positions received as infections and healthcare patients all preventing Neutrolin research, on within ratings that This popular catheter-related by providers. providers clearly

that product the was on done over on a including as and The treatment and therapy. current with the very-high. the states tested percent profile Neutrolin research by XXX to firm interest has based receptibility new XX across physicians, Neutrolin top among was products similar disease fact, conducted cell such research products was research market of In all and product nurses market in many modalities, very-innovative a

of of assessed was deep further solution detailed the solution. and lock oncology of were that catheter a undertook TPN. segment lock also required CorMedix work. were segments catheter The ICU studied The analysis hemodialysis, the three size these and detail. segments markets The in

in number omnibus easy is within not each catheter these in it’s no available any determine U.S. As of that solutions information or of in or data used to the markets the lock accurately capture of segments this reports there these IMS the markets,

around flushes, catheter solutions. team separates outcome solutions and combined lock some sometimes regulatory from which commercial segments and per as This supply findings. in lock growing. finance lock The XXX million catheter growing. The for year misunderstood was chain participated. and to also lock catheter solutions TPN segment information into and the to market catheter hemodialysis and oncology cross-functional medical almost solutions were revealed catheter be of affairs, estimated estimated million interesting per are The be XX CorMedix’s year lock solutions

used flash instead. We port as on be that the in access believe oncology is while with is lock catheter, by often are route segment, today’s would venous based interesting is used most for central followed solution. hemodialysis catheters saline a practice, the What that catheter also a primary

our can to gained in Having these oncology way these segments. the presentation our address markets value market to hemodialysis variation us further the the product and different of different tailor packaging, learned insight and in markets, pricing that a address have and in how we between allows product with best needs

renal in end in on patient and the stage stands focus Drug the the understanding disease. The CorMedix hemodialysis reimbursement work issued Adjustment for separate and holders. the summer Time Payment value pricing Add-on effort also of budget was legislation burden TDAPA that that on impact population. different was of CRBSI for A called XXXX, examined was the spent initially Transitional

this all ESRD to biologicals, of the year outside the at Neutrolin eligible the of CMS What to drugs’ is bundle for include new least for first provide generic years. drugs. illegibility TDAPA expanded including reimbursement two be for would last

drug CMS new the eligibility as FDA just ingredients drug therefore general, approvals for biologics active month for XXXX. Neutrolin TDAPA. still approved of and last be and to new a new this TDAPA. exclude and would approvals. molecule criteria for combination, drugs a entity to released In entities, new and new should biologics proposing drugs remain is CMS a eligible falls eligible within proposal to under certain narrow criteria with as new molecule types

group quite the total patients patients nutrition oncology higher AFP system the codes. TDAPA Plus, only. are treated treated a smaller in different. oncology, in more in On is The a parenteral The via TPN, are capitated majority TPN are segments, hemodialysis is In words, for This payment leveraged, fee-for-service hospital segments outpatient. generally price. which of generally applies based the as on reimbursement these reimbursement DRG large model, other which in while outpatient the is

value completed of There we need is payout work for Neutrolin the CorMedix the still our pricing lot more in to to order messaging For strategy. be and before due budget optimize strategy economics, health in and finalize to value refine done to impact, can be higher CRBSIs. incidence were such strategy Work U.S. a as

shareholders’ segment, me launch we to while open prepare hemodialysis market, be clear, same being value. a are very Because the potential time payer Let our at hemodialysis in to CorMedix to partnerships. maximize is continuing goal Neutrolin to concentrated provider is the

to We access medical CorMedix, commercial are recruit market. U.S. now and affairs the the for leadership market into beginning process the

a be space that already in care appropriate best therefore these value. particularly who to strategic acknowledge maximize shareholders’ in and care broad this be would area a TPN, able of larger, also in more more is very the that critical We oncology, and

me ask finance Now, quarter CorMedix to Bob finances. let two and cover

Bob Cook

Thank very Khoso. much, you

ended The you XX, financial our I the Company results. read for second file urge quarter Form and more report its XXXX, expects to complete XX-Q contained of months to information discussion the six tomorrow. in report on for June a the

approximately our loss $X.XX quarter was the million to share $X.X our million respect second loss net of With share financial XXXX. in per $X.XX the $X.X XXXX or net results, or of with per compared

recorded SG&A Jersey sale declined XXXX in second an proceeds we New operating of increase the R&D quarter, in while resulting cash our expenses million. $X.X of losses, we During recorded net expense. significantly

Operating expenses in by $X compared XXXX quarter million, the million last million $X a to mainly offset clinical declined a to expense, trial declined $X.X $X.X approximately in the R&D second XX% quarter of increase to second XX% million with $X.X of year. million expense CMC-related due partially $X.X decrease million in in from activities.

$X.X XX% and staffing, investor in second relations marketing with expenses, XXXX. million of Higher fees, SG&A partially compliance compared and expenses $X.X expense increased were by to expenses. quarter million a consulting offset in reduction patents legal the

recorded received $X.X operation in lower this million, We during of Jersey positive used from million the compared $X.X from year cash in the as quarter of cash last sale second operating a operations of and with of cash of our expenses quarter the year. second NOLs, of New result the

compared loss XX, or six XXXX. our $XX.X six months the for the net respect loss financial or of $X.X approximately share for a with million months June XX, net June XXXX, share With $X.XX our ended was per million results $X.XX per to ended

year of wind expense. million months half of in compared despite the a a this of $XX.X million, XX% with in Operating an LOCK-IT-XXX XXXX, expense the trial, six of declined $XX.X amounted XX%. of CMC-related $X.X result reduction R&D to increase the down first first as during to expenses million

the last Relations were with and of fees Investor decline Higher staffing increased during approximately compared compliance patent in year. with SG&A consulting legal expense period first expenses, recorded expenses. in half XX% and costs and the

of with of used of operating compared used XXXX. reduction the receipt in a the of first during approximately lower the XXXX of year as result half expenses Cash was occurred cash in mainly cash of million half operations used New in sale the $XX.X half NOLs. cash the $X.X for Jersey the the and first operations first million, in throughout The

the the with operating balance from cash June timing by $XX.X cash the XX, NOL operations, strategy for the driven The we next received we the including third funds we June by the existing to lower expenses at and sale, and the XXXX. believe amounts NDA anticipated Company had during initial a respects amount XX, necessary NDA As by investments adopt commercial in preparations we result on and at of second the quarter the of as submission sheet continue XX, of our our into almost to Neutrolin's of plus the Based will cash our the timing at same any short-term we commercialization million in of have on March and reported investments raised Neutrolin capital be U.S. future the the and and quarter launch market. approval year. short-term

designed implement to thereby optimize a commercialization realize to expect We and returns. successfully shareholder value plan Neutrolin's commercial

that, hand to call the for With Khoso will remarks. his back now I Khoso? closing

Khoso Baluch

you, Thank Bob.

management clinical U.S. insight into Jack successfully to and Neutrolin you provide the focused you over Bob complete I'm Phoebe, a corporate about has to efforts undertook the that and emphasize, provide the on making which with to pleased major application we three been like and in the team our marketing to have extremely have we data XXXX we shareholders last LOCK-IT-XXX met. occurred What are pleased months. progress we in to objective work hopefully support the report the that this for covered required

the with and the in elaborated, chain project for quality and market. both the the the now Company’s focused tremendous. provided invested insights effort parallel flow. into the work off. As has Phoebe current continuing The cash CMC the the sheet FDA And Bob on supply paid the U.S. preparation discussed balance Jack has upcoming meeting team of team The been current work and progress FDA the high in, the on components. NDA is

in CVC the users. become for the standard catheter related population of approved, Neutrolin bloodstream we believe infections will care If of preventing

we to evolve strength of XXXX and our works of our strategy in quarters continue the on embarked ever increasing continue in move over we study the I'm to areas strategic the augmenting will management team with by pleased confident team, at coming forward an need. also will pace. that very I'm early

forward look now, CorMedix your continued release updates you operator. and and Thank to calls. website, of via hand support material development I And this I'll back press CorMedix. for to providing our conference with you the

Operator

you. The H.C. open Our [Operator Thank your first floor for is comes question Ram questions. Please of now question. from Selvaraju Wainwright. Instructions] state

Ram Selvaraju

questions. Thanks very taking much for my

you I particularly just elaborate aspects. know wanted this So, as to could if the structure pertains regarding Neutrolin, environment for three important to

framework, principal framework. as this pertains TDAPA ascertain think the I pricing Payment TDAPA, you to but Add-On potentially proposed from or Drug which wanted the about the what Firstly, are believe CMS changes takeaways or especially the I talked key previously, impacts to you Transitional to

be and be the talk beyond perhaps you you would potentially positioning you. into, schedule. most lastly, there to quarterly to perhaps that Medicaid perspective the from J-code broader formulary mean Thank specific CMC’s this the a in and shift reinvestment CMS that likely fall what about could to from And talk applicable of to decision And particular, if category Medicare drug access might could may if the Secondly, could context? about Neutrolin? Neutrolin codes positive impact the be and of what

Khoso Baluch

Ram, for Thanks, questions. your

it. a stab at Let answering me take

have that and got allow I right framework, they of strides would in think, and new where TDAPA that things the they products to will fits stand obviously chemical to a innovation to the Neutrolin way bundle very marketplace, of clearly entity now good. products to the be bring is out pricing narrow the the So, benefit into it. focus of terms that, outside clearly

doing J-code basis get of doing you would on have because the of that the a period actually products long what when market, requested frequent these happen get quarterly do a benefit have these is J-codes codes. get what than codes, more they a you it. faster need depending were to on review, wait your the you newer these terms to you the deadline In have come and that normally previously before because And missed helps get than may have you approval, addition to

In only of working from market terms Clearly, of catheter our data as we What there the is to have we lock be the early comment to to terms that right and significant a in with now in the out heparin solution on lock that seen the on it’s it. we’ve marketplace. used to formulary, therefore improvement heparin. is solutions, bit our what research possible. get be would soon done, Neutrolin formularies a we And formularies as clearly is will catheter

Ram Selvaraju

a Great. Thanks. just follow-up then, very if may. I And quickly

under Regarding would process, going this what as memory to how us to can my many of Thank there just you the modules sense, filing refresh a be you give expect timing submission? whether the NDA and intervals is to different there be modular rolling submission to with you. modules a kind filing process, respect be, the of the

Phoebe Mounts

insightful. very That’s question. the for you Thank

be understand at the some meeting. to issues of that pre-NDA the with addressed need clearly You FDA

details pointed there need option So, out submission. administrative the a of addressed. to lot rolling of that you be are And

Track comments noted that from call, during we I the Fast in submission to FDA. my us eligible makes designation As rolling from received FDA request have

request that modules in be if we and that’s is a position to sequence so, and submission then select of specific part FDA, will to And granted, negotiation. for

of are package process. preapproval review As have CMC I’m part sure challenge completed a lot the the and to for inspection during is by FDA scheduled you aware, of the

is possible. there in successful NDA. clearly important by clearly as fast and agency section section clinical for those completed having preapproval is the assigned CMC approval so advantages first, of the So, review as and inspections be can very The going the

that's submission. So, another section that may for considered priorities for be

pre-NDA agreed submissions the the and of with and timing will the upon FDA and the negotiated be of module Thank certainly, So, meeting. sequence you. at discussed the

Ram Selvaraju

a than a it would the available, module few timing readily -- the as the though, submission, months the I wouldn't module intervals is right? assume more if just clarification different the that between take of between information the data So, submissions,

Phoebe Mounts

as Few we as certainly months can, to as that is can do. as We're Thank make a forces gather it long time. shorter. to fast doing much moving process efficient We're you. working we very the and hard

Ram Selvaraju

it. you Thank much. I so appreciate

Operator

ladies And I back session. conference Baluch gentlemen, question-and-answer comments. our for the turn this to now over will will Khoso conclude and closing

Khoso Baluch

like attending appreciate support. enter this for Thank thank as It's I’d We your much. The you very opportunity really this call. phase. is everyone the we And next to for Company exciting there. an time

continue a us. So, the And going bring Neutrolin here clearly to very is we forward team quality be to go important I great and is with have market. what as to

So, Thank all for your support. thank you very much you.

Operator

your conclude teleconference. Thank for participation. We you thank This today's does you.

You may day. disconnect your and have great lines at this a time

CorMedix (CRMD) 13 Aug 192019 Q2 Earnings call transcript